Tricuspid atresia secondary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(21 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Template:Tricuspid atresia}}
{{Template:Tricuspid atresia}}
{{CMG}}; '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [[mailto:psingh@perfuse.org]]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [[mailto:kfeeney@perfuse.org]]
{{CMG}}; '''Associate Editor-In-Chief:''' {{Sara.Zand}} [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu] [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu]


Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Overview==
==Overview==
Secondary prevention strategies following the Fontan procedure include serial checking [[EKG]], [[Transthoracic echocardiography]], [[Pulse oximetry]], [[Holter monitoring], [[Cardiac MRI]], [[Exercise test]].


==Secondary Prevention==
== Secondary Prevention ==
===ACC/AHA 2008 Guidelines - Recommendations for Endocarditis Prophylaxis - Tricuspid atresia (DO NOT EDIT)===
Secondary prevention strategies following the Fontan procedure include:<ref name="StoutDaniels2019">{{cite journal|last1=Stout|first1=Karen K.|last2=Daniels|first2=Curt J.|last3=Aboulhosn|first3=Jamil A.|last4=Bozkurt|first4=Biykem|last5=Broberg|first5=Craig S.|last6=Colman|first6=Jack M.|last7=Crumb|first7=Stephen R.|last8=Dearani|first8=Joseph A.|last9=Fuller|first9=Stephanie|last10=Gurvitz|first10=Michelle|last11=Khairy|first11=Paul|last12=Landzberg|first12=Michael J.|last13=Saidi|first13=Arwa|last14=Valente|first14=Anne Marie|last15=Van Hare|first15=George F.|title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease|journal=Journal of the American College of Cardiology|volume=73|issue=12|year=2019|pages=e81–e192|issn=07351097|doi=10.1016/j.jacc.2018.08.1029}}</ref>
 
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa is reasonable in those patients with the following indications: <nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.'''Prosthetic cardiac valve.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.'''Previous infective endocarditis (IE).''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''c.'''Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''d.'''Completely repaired CHD with prosthetic materials, whether placed by surgery or catheter intervention, during the first 6 months after the procedure.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''e.'''Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with the following indications:<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.'''Prosthetic cardiac valve or prosthetic material used for cardiac valve repair.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.'''Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}


{|class="wikitable"
*[[EKG]]
|-
*[[Transthoracic echocardiography]]
| colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]]
*[[Pulse oximetry]]
|-
*[[Holter monitoring]]
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.'''Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy or colonoscopy) in the absence of active infection.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
*[[Cardiac MRI]]
|}
*[[Exercise test]]


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Needs content]]
[[Category:Cardiovascular diseases]]
[[Category:Cardiovascular system]]
[[Category:Cardiovascular system]]
[[Category:Cardiology]]
[[Category:Cardiology]]
Line 48: Line 25:
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Needs content]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 19:56, 8 November 2020

Tricuspid atresia Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Tricuspid Atresia from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenarios

Pregnancy

Case Studies

Case #1

Tricuspid atresia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid atresia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tricuspid atresia secondary prevention

CDC on Tricuspid atresia secondary prevention

Tricuspid atresia secondary prevention in the news

Blogs on Tricuspid atresia secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Tricuspid atresia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Secondary prevention strategies following the Fontan procedure include serial checking EKG, Transthoracic echocardiography, Pulse oximetry, [[Holter monitoring], Cardiac MRI, Exercise test.

Secondary Prevention

Secondary prevention strategies following the Fontan procedure include:[1]

References

  1. ↑ Stout, Karen K.; Daniels, Curt J.; Aboulhosn, Jamil A.; Bozkurt, Biykem; Broberg, Craig S.; Colman, Jack M.; Crumb, Stephen R.; Dearani, Joseph A.; Fuller, Stephanie; Gurvitz, Michelle; Khairy, Paul; Landzberg, Michael J.; Saidi, Arwa; Valente, Anne Marie; Van Hare, George F. (2019). "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease". Journal of the American College of Cardiology. 73 (12): e81–e192. doi:10.1016/j.jacc.2018.08.1029. ISSN 0735-1097.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Tricuspid_atresia_secondary_prevention&oldid=1674655"